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Abstract The classification of the endoscopic appearance of
superficial neoplastic lesions of the digestive mucosa aims to
evaluate the risk of progression to advanced neoplasia in 3°
(low, intermediate, high) and to predict appropriate treatment
and corresponding surveillance. The privileged position of
endoscopy results from its double impact on prevention of
digestive cancer through reduction in incidence after early
detection and eradication of precursors; and through reduction
of mortality after detection and treatment of cancer at an early
and curable stage. However the efficacy of diagnostic
endoscopy still requires improvement and quality control on
the following points: (1) technology, with a generalized use of
the recently introduced high-resolution endoscopes. (2)
diagnosis of poorly visible nonpolypoid precursors: this
applies to small depressed lesions and large slightly elevated
or sessile serrated and non-serrated precursors, particularly in
the proximal colon. (3) treatment and training in therapeutic
endoscopy, including the most recent techniques of mucosal
resection of nonpolypoid lesions.
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Introduction
Gastroscopy and colonoscopy, as the most generalized
endoscopic procedures, are adapted to detect the large
majority of digestive cancer in the esophagus, stomach and
large bowel. The IARC Globocan database [1], estimates
that cancer located at these three sites account for 24% of
the World cancer mortality in the year 2002. In the aging
population of the world, cancer mortality is still expected to
increase because of the growing importance of age classes
over 60 years. Endoscopic diagnosis of less frequent tumors
by enteroscopy or biliopancreatic endoscopy will not be
analyzed in this review.
Early detection of cancer at a curable stage and of
premalignant precursors may occur in persons complaining
from non-specific digestive symptoms, or compliant to a
screening intervention. Digestive endoscopy is the gold
standard in early detection and has a therapeutic potential.
Endoscopic diagnosis underwent a dramatic progress in recent
years with high resolution video-endoscopes, optical and
electronic magnification and image processing. In relation to
this new technology, the strategy of endoscopic diagnosis
needs to be revised. This review aims to summarize the
morphologic classification of superficial neoplastic lesions in
the mucosa of the esophagus, stomach and large bowel and to
present a strategy of endoscopic diagnosis based on the
prediction of the risk of malignancy in the detected lesions
prior to treatment decision.
Burden of digestive cancer
Tumor sites in the digestive mucosa
In the absence of hiatal hernia, the esophagus joins the
stomach at the level of the diaphragmatic pinch and the
squamo-columnar epithelial junction, or Z line is located
just above the pinch of the diaphragm. Just above the Z line
the stratified squamous epithelium shows characteristic
features: palisade vessels and small islands of ectopic
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cancer is much more common than adenocarcinoma. At the
esophagogastric region, confusion may arise between
adenocarcinomas developed in the distal esophagus and
gastric tumors developed in the proximal stomach. Adeno-
carcinoma in the stomach includes two sub-sites: proximal
(cardia cancer) and distal (non-cardia cancer in the corpus
or antrum). Adenocarcinoma in the large bowel is called
proximal, or right sided, when located in the cecum,
ascending colon, and transverse colon and distal, or left
sided, when located in the descending colon, sigmoid and
rectum. The intra-luminal fermentation and the bacterial
enzymes involved in the generation of mutagenic metabo-
lites are confined to the proximal colon and environmental
factors may have a distinct impact on the incidence of
proximal and distal tumors.
Parameters in epidemiology
The burden of digestive cancer (incidence, mortality,
survival) is assessed in descriptive epidemiology. New
incident cases of cancer are reported in population based
cancer registries [2–4]; however in many countries regis-
tration is limited to a fraction of the country. Registries files
are completed by other sources, including death certificates,
medical insurances and other databases [5, 6]. The annual
number of new cases (Incidence) or of deaths from the
same disease (Mortality) is reported as a crude rate for
100,000 persons of the population; the crude rate represents
the actual burden of cancer at the period selected. The
comparison of the risk between two populations differing in
their distribution of age classes, requires an adjustment to a
modelized world population; the age adjusted or standard-
ized rate (ASR) is established for incidence or mortality per
100,000 persons. Adjustment is also required in the
comparison of the risk between two periods in the same
country; then the rate is adjusted to the age structure of the
population of this country in a fixed year. The global
burden of cancer in each country of the world is also
evaluated through estimations as in the GLOBOCAN
database [1]. Here the worldwide burden of colorectal
cancer is estimated in 2002 at 1,023,200 incident new cases
and at 529,000 deaths. The respective estimations are
462,000 new cases and 385,900 deaths for esophageal
cancer and 904,000 new cases and 700,300 deaths for
stomach cancer. Data on survival are extracted from
registries with follow-up. The 5-year relative survival (5-y
RS) describes the percentage of patients alive 5 years after
the diagnosis while eliminating other causes of death.
Heritable cancer
In the esophagus hereditary cancer is exceedingly rare but
has been observed in relation with Palmoplantar kerato-
derma (Tylosis). In the stomach hereditary cancer is also
rare and caused by a germline mutation of the regulatory
gene (16q) encoding E-cadherin. Gastric cancer (intestinal
type of Lauren) may occur in other genetic syndromes:
hereditary non-polyposis colon cancer and hereditary
gastrointestinal polyposis (FAP and Peutz-Jeghers syn-
drome). In the colon hereditary cancer, represents near to
5% of all cases; the two major categories are the FAP and
the HNPCC syndromes.
Temporal variations in incidence
Temporal variations of the age adjusted incidence are
caused either by environmental factors or by a policy of
prevention and early detection.
Squamous cell cancer in esophagus The ASR incidence/
100,000 (adjusted to world population) is low, in the range
5 to 15, in most Western countries. The incidence is higher
in regions with a low socio-economic status and nutritional
deficiencies in Asia [7, 8], Northern India and Western
China and in South Africa (Transkei). The ASR incidence/
100,000 (adjusted to world population) for the period
1993–97 in Cixian county adjacent to Linxian county in
China is 183.3 in men and 123.1 in women [2]. In Western
countries where most cases develop in relation to alcohol
and tobacco consumption; a decreased in incidence occurs
over the past 20 years in men, in relation to decreased
consumption of alcohols. In regions of Asia, Africa, at high
risk for esophageal cancer, common factors in diet and
environment cause a chronic inflammation of the mucosa
with esophagitis and cancer; recent surveys indicate that
incidence decreases, perhaps in relation with improved
socio-economic status. The 5y-RS is low; as an example the
median figure is only at 12.3%, in cancer registries of the
European Union during the period 1995–99 [5].
Adenocarcinoma in esophagus The tumor develops in a
segment of columnar metaplasia called a Barrett esophagus
[9–13]. The risk of malignancy in columnar metaplasia is
evaluated as one case for 200 years-patient. In registries
without histology subgroups, the incidence of adenocarci-
noma is joined to that of squamous cell cancer. In period
1998–2002, the respective proportions of adenocarcinoma
are given by registries with histology subgroups for
esophageal cancer [2]. The figures were high in the USA
and northen Europe: 59.5% for the white non Hispanic in
the USA [4], 44.9% in Denmark, 53.0% in Netherlands.
Much lower figures occurred in other countries: 4.1% in
Japan [3], 3.9% in Brazil (Sao Paulo registry). There is a
contrast between the increasing incidence of adenocarcino-
ma in the esophagus with the stable or decreasing incidence
of adenocarcinoma at the cardia during the last quarter of
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the XXth century [11]. Several studies have shown that an
increased risk of neoplasia in columnar neoplasia is linked
to Caucasian ethnicity, male sex, old age, alcohol con-
sumption, continuous smoking, dietary deficiency in fruit
and vegetable and a long history of reflux symptoms.
Adenocarcinoma in stomach This tumor is still the second
most frequent cause of death from cancer. The localization
in the proximal stomach or cardia, is less frequent than in
the distal stomach, which accounts for more than 80% of
cases [14]. The risk of gastric cancer in men is about twice
that of women. Areas of high incidence occur in Eastern
Asia (Japan, Korea, China), Western South America and
Eastern Europe [12–14]. In 1998–2002 period the ASR
incidence/100,000 (adjusted to world population) [2] is 7.2
in men and 3.4 in women in the USA [4]; the respective
figures are 7.1 and 3.2 in Denmark; 51.3 and 19.8 in Japan
[3], 43.1 and 16.0 in Chile (registry of the Valdivia
province). The causal factor is chronic atrophic gastritis
provoked by H. Pylori. The worldwide declining incidence
of distal stomach cancer is attributed to environmental
factors in diet and control of H. pylori infection. In Japan
[3], the incidence decreased during the period 1963–89 by
47% in men and 43% in women. In Western countries
where most cases are detected at an advanced stage the 5-y
RS is still low in 2002–2004 with a median value at 24.9%
in European Countries [5] and 25% in the USA [4]. The
higher proportion of tumors detected at the localized stage
in Japan explains a higher survival: 47% in the Osaka
registry in the period 1987–89.
Adenocarcinoma in colon and rectum This tumor is the
second most frequent cancer. The incidence is high in
countries of North America, Europe, Australia and in Japan,
and still low in developing countries of Africa and in
central Asia. In 1998–2002 the ASR incidence /100,000
(adjusted to world population) [2] is 38.6 in men and 28.3
in women in the USA [4]; the respective values are 37.4
and 21.7 in Japan [3], and 39.3 and 29.8 in Denmark. The
Ocidental style of life with a higher alimentary intake,
excess weight shown in the variation of the BMI and
decrease in physical activity explains the increased inci-
dence. The generalization of this life style occurs in
emerging countries and also in Japan where the ASR
incidence/100,000 persons (adjusted to Japanese popula-
tion) passed from 10,9 in 1975 to 43,8 in 1999 in men [6].
Noteworthy the development of early endoscopic detection
and treatment of precursors in developed countries explains
the temporal decrease in incidence, while survival is
increasing. In the USA [4] during the period 1975–2002,
the 5-y RS progressed from 50.2% to 65.4% in men; and
from 52.3% to 66.3% in women. In Japan the 5-y RS
progressed from 37.1% in 1962–66 to 71.7% in 1992–96 in
men; the respective values in women were 32.8% and
72.1% [6]. In registries from the European Union [5] the 5-
y RS (both sexes) of colorectal cancer slightly progressed
from 54% in the period 1995–1999 to 56.8% in the period
2000–2002.
Precursors and premalignant lesions
A precursor is the temporal ancestor of a neoplastic
premalignant lesion; this definition applies to chronic
inflammation of the digestive mucosa as chronic esoph-
agitis in some regions of Asia and Africa, columnar
metaplasia in the esophagus, chronic atrophic gastritis in
the stomach, chronic inflammation of the colonic mucosa in
inflammatory bowel disease. However a neoplastic lesion
will never develop in the majority of precursors and the
place where it may arise within a diffuse alteration of the
mucosa cannot be determined. The assessment of a
precursor as a “preneoplastic” lesion depends upon the
presence of reliable histological criteria and of molecular
markers: the most common molecular alterations are
mutations in the suppressor gene TP53 (17p13), encoding
p53, inactivation of P16/CDKN2A (9p22), encoding p16,
amplification of CCND1, encoding Cyclin D1, and over-
expression of proto-oncogenes such as the EGF receptor or
c-Myc. Neoplastic lesions develop in a normal epithelium,
or in a mucosa diffusely altered by a precursor and
preneoplastic condition. Neoplastic lesions are circurm-
scribed alterations with cell atypia, architectural disorgani-
zation, and evidence of hyperproliferation, which carry a
significant risk of progression to malignancy.
Squamous cell cancer in esophagus Reflux esophagitis in
the Western World is not a precursor of esophageal cancer
and patients with gastroesophageal reflux and chronic
erosive esophagitis are not at increased risk for cancer [1].
However chronic erosive esophagitis in alcoholic patients is
a preneoplastic condition. In Asia and Africa the role of non
erosive chronic esophagitis as a preneoplastic condition [11,
12] has been suggested (but still debated) owing its very
high prevalence in the regions with high prevalence of
esophageal cancer (Henan, China and Transkei, South
Africa).
Adenocarcinoma in esophagus Columnar metaplasia in the
esophagus is a preneoplastic condition [10–12]. There is
still debate with respect to the requirement of intestinal
metaplasia to the status of preneoplastic condition. Based
on endoscopic series conducted in a random sample of
population, the prevalence of columnar metaplasia in the
adult population is estimated at 1.6% in a study conducted
in Sweden [13]. In Asian populations the prevalence is
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lower. The risk of cancer increases with the length of the
segment, but short segments deserve as much attention
because they are more frequent. The surgical correction of
reflux does not suppress the risk of cancer.
Adenocarcinoma in stomach Chronic atrophic gastritis in
the mucosa infected by H. pylori is a preneoplastic
condition [15, 16]. The sequence leading from chronic
gastritis to gastric cancer has been described by Correa [15]
and occurs in most cases of cancer. The progression to
cancer is slow low grade intraepithelial neoplasia and rapid
in a few months high grade intraepithelial neoplasia. The
Lauren classification of gastric adenocarcinoma is based on
2 categories: a “intestinal” type with recognizable glands
and a “diffuse” type without cohesion between the
malignant cells. Adenocarcinoma with a tubular, papillary,
mucinous or signet ring cell pattern is classified as well,
moderately, poorly differentiated.
Adenocarcinoma in colon and rectum Chronic inflamma-
tion plays no role in the development of most neoplastic
lesions of the colorectal mucosa. However the chronic
inflammatory changes occurring in Ulcerative Colitis and in
Crohn’s disease can be considered as preneoplastic pre-
cursors. Until recently, it was assumed that all colorectal
neoplastic lesions developed through the single sequence of
polypoid adenoma cancer with mutations involving APC
inactivation, KRAS mutation and TP53 inactivation in the
sequence. New molecular approaches, based on DNA
sequencing with polymerase chain reaction (PCR), have
demonstrated distinct colon cancer classes and genomic
profiles in nonpolypoid adenomas [17]. Furthermore ser-
rated lesions provide a common pathway between neoplas-
tic and non-neoplastic lesions and a fraction of hyperplastic
polyps are preneoplastic lesions. As in the stomach
colorectal adenocarcinoma is classified as well, moderately
or poorly differentiated.
Superficial neoplastic lesions
The premalignant, or malignant, neoplastic lesions of the
digestive mucosa are called superficial when the endoscop-
ic appearance suggests that invasion is limited to the
mucosa (m) or the submucosa (sm). They are classified as
type 0 in Japan and in the Paris classification [18], while
advanced and non superficial cancer is classified in types 1
to 5. The gross morphology of type 0 lesions is described in
subtypes: - type I polypoid, with variants pediculated or
sessile (Ip, Is), - type II nonpolypoid, with variants slightly
elevated, flat or slightly depressed (IIa, IIb, IIc) -type III
ulcerated. The proportion of nonpolypoid lesions is
estimated in various studies from Japan at 84% in
esophagus, 95% in the stomach and 49% in the colon
[18]. The morphology has a prognostic value, irrespective
of the size of the lesion and the depressed (0–IIc) type, in
spite of being rare plays a significant role as precursor of
advanced cancer.
In type 0 lesions, pathologists stratify the risk of cancer
according to the Vienna classification [19]. Groups 1
(negative for neoplasia) and 2 (indefinite for neoplasia)
correspond to a preneoplastic condition. Groups 3 (low
grade intraepithelial neoplasia) and 4 (high grade non
invasive or invasive intraepithelial neoplasia) correspond to
a neoplastic lesion. Group 5 corresponds to cancer with
invasion of the submucosa. In the columnar type of
epithelium high grade premalignant non invasive lesions
are included as well as intramucosal invasive lesions in the
same Group 4 of the Vienna classification. In the squamous
epithelium intramucosal cancer is classified as intraepithe-
lial, microinvasive or intramucosal.
The terminology “early cancer” is also used for a
malignant superficial neoplastic lesion and assessment of
invasion in the submucosa is critical for the risk of nodal
metastases. A micrometric measure of the depth of invasion
from the lower limit of the muscularis-mucosae helps to
control the legitimacy of localized treatment by endoscopy.
The empirical cut-off limit of invasion is 200 µm in the
squamous stratified epithelium of the esophagus, 500 µm in
the columnar epithelium of the stomach and 1,000 µm in
the columnar epithelium of the colon. In addition to depth
of invasion, the presence of qualitative indices of poor
prognosis (tumor grade, images of vascular invasion, tumor
budding) is explored.
Endoscopic diagnosis
With high resolution electronic video-endoscopes coupled
to HDTV standard, image processing increases the contrast
of the mucosal surface as in the Narrow Band Imaging
(NBI) or FICE techniques [20–26]. The architecture (pits
and ridges) of the normal mucosa is now described in
magnification up to × 150 with the optical and electronic
zoom, including the description of epithelial types as shown
in Barrett’s esophagus [27] As an approach to in vivo
cytology or histology, magnification up to ×1,000 is
reached with the endo-cytoscopy probe or with Confocal
Laser Endomicroscopy [28–30]. The improved technology
is not a substitute to a careful exploration of the mucosa
during endoscopy. The analysis of the lesion is even more
important than before because more abnormalities are being
visible. Endoscopic diagnosis is not a single step
procedure: - First is the detection of an area with an
abnormal apperance - Second is the characterization of
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the target area - Third is treatment decision, based on a
pragmatic classification [31].
Detection
Small lesions can be masked by any solid and liquid matter
persisting at the surface of the mucosa. The exigence of
complete cleanliness of the digestive lumen applies to the
large bowel after a cathartic preparation but also to the
upper digestive tract where all particles inside the stomach
should be removed with a jet of water and aspiration.
During upper GI endoscopy or colonoscopy the surface of
the mucosa is explored sector by sector, including blind
zones. Abnormal areas are detected in standard vision
without image processing and chromoscopy, on any of the
following elements: - obvious elevation or depression; -
mucosal discoloration—interruption of the course of
superficial capillaries. Polypoid, sessile or pedunculated,
neoplastic lesions are conspicuous, even when small, but
can be missed in blind areas. Nonpolypoid lesions, even
large, can be missed when the operator lacks cognitive
training for a slight change in color of the mucosa.
Special attention is required in the exploration of the
proximal colon, where poorly visible lesions are often
covered by bile stained mucus. Then, the morphology
and limits of the lesion are described with chromoscopy.
The non absorbed dye, a solution of indigocarmine (0.5%),
can be used everywhere; other absorbable dyes have specific
indications: the iodine-potassium iodide (1.5 to 2%), the
acetic acid (3 to 5%), methylene blue (0.5%) in the stomach,
crystal violet (0.2%) in the colon. The size of the lesion can be
measured with a gauge, or classified as diminutive (up to
5 mm), small or intermediate (6–9 mm) or large (10 mm and
more) and the morphology is classified in the subtypes of the
Paris classification.
Characterization
Characterization classifies the lesion prior to pathology, in
introduction to treatment decision based on the evaluation
of the risk of malignancy in lesions with a neoplastic
appearance [3–34]. Therefore the rules of the analysis are
the same for premalignant precursors and for superficial
cancer. The histopathology prediction is based at first on
gross morphology (Figures 1, 2, 3, 4 and 5): in non depressed
lesions (type 0-I, IIa, IIb) the risk of invasive malignancy
increases with the size. In depressed lesions (type 0-IIc) the
risk occurs even if they are small and less than 6 mm in
diameter. Then the surface microarchitecture is analyzed
with magnification, combined with dye chromo-endoscopy
and the network of superficial capillaries is analyzed in
transparency. The NBI technique has recently confirmed its
efficacy in this analysis.
The gross morphology
In the esophagus the usual morphology of superficial
squamous cell cancer is flat or depressed; in a metanalysis
of 143 centres conducted in Japan the distribution in the
subtypes was as follows: 0-I in 2.2%, 0-IIa in 12.6%, 0-IIb
in 31.4%, 0-IIc in 53%, 0-III in less than 1% [18]. In the
columnar lined esophagus superficial premalignant lesions
and adenocarcinomas are suspected on the basis of slight
surface irregularities, spots with color change, or variations
in the network of superficial vessels. Pediculated polypoid
(-0-Ip) lesions are rare, esophageal ulcers are associated to
fibrosis and strictures, mixed types of tumor associate
sessile nodules, often multiple and a depressed area.
In the stomach superficial premalignant lesions and
adenocarcinomas appears ad discolored (pale or red) areas in
the mucosa, with minimal alterations of the surface after
chromoscopy. Most neoplastic lesions are flat or depressed
(type 0-II c). The large majority of polypoid lesions
corresponds to non-neoplastic polyps (fundic cystic polyps
and hyperplastic polyp). Premalignant gastric lesions are
described as flat adenomas or depressed adenomas. Malignant
lesions are described as early cancer. In Japan, during National
Screening Campaigns, around 70% of type 0 gastric cancer
show this nonpolypoid depressed morphology.
In the colon, the morphology of adenomas is often
polypoid, pedunculated or sessile, and classified in subtypes
0-Ip and 0-Is of the Paris classification. The direction of
growth of those adenomas is upwards, increasing in volume
more than in depth across the colonic wall. The majority of
polypoid adenomas are small and adenomas larger than
10 mm are often called “advanced” as well as those showing
at least a 25% villous architecture, or high-grade intra-
epithelial neoplasia. The majority of nonpolypoid and non-
depressed adenomas are classified in subtype 0-IIa, just as the
majority of non-neoplastic hyperplastic polyps [34]. Large
adenomas with a growth pattern more lateral than vertical
and a global nonpolypoid morphology are called Laterally
spreading tumors (LST) and are classified in two groups:
Granular with an homogeneous or nodular surface (0-IIa or
IIa + Is) and non granular with an even surface often
depressed, (0-IIa or IIa + IIc). Depressed adenomas (subtype
0-IIc) account for only 5% of superficial neoplastic lesions
but show a higher proportion of submucosal invasion than
other sub-types. Depressed 0-IIc lesions differ from the so-
called “flat depressed adenomas” by the abrupt edge of the
central depression. In Japan, submucosal invasion occurred
in 35.9% of superficial depressed lesions in the very large
series (n=25,862) collected in the Akita and Yokohama
Hospitals in Japan and in 27% of the series (n=12811)
collected in the Hiroshima University Hospital [18, 34].
Sessile serrated lesions are large, with a size over 10 mm in
diameter, and follow a predominantly lateral growth pattern.
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Their general morphology is nonpolypoid (0-IIa, or IIa + Is).
The surface of the lesion is homogenous and often covered
with a yellow mucous layer; sessile serrated lesions have a
significant risk of progression to serrated adenoma. Serrated
adenomas offer a polypoid or nonpolypoid morphology,
corresponding to the subtypes 0-Ip, Is or IIa.
The microarchitecture in surface
The surface microarchitecture of the epithelium (depres-
sions and ridges) is visible when using NBI or chromo-
scopy with the optical zoom or the objective macro.
In the squamous epithelium of the esophagus the surface of
the normal epithelium has a smooth appearance with a clear
pink color. In areas with neoplasia the spontaneous colour is
changed before using the chromoscopy with the the iodine-
potassium iodide solution [35]. In the irregular surface the
most patent change is in the regression of the multiple red
dots corresponding to the intrapapillary capillary loops
therefore in exploring the microvascular network [25].
In the columnar lined esophagus, characters highly
suggestive ofneoplasia include an abrupt change in the
average size of the epithelial crests (from large to small)
with irregular and distorted pattern, the presence of areas
with an amorphous surface and abnormal corkscrew micro-
vessels [21].
In the stomach the most frequent aspect of the surface of
early gastric cancer is gyrus and villous pattern in place of
round pits; the epithelial crests are either regular or
irregular; an amorphous pattern of surface is suggestive of
submucosal invasion [24].
In the colon the surface microarchitecture of epithelial
pits, grooves and crests is classified in the subtypes of pit
pattern mostly described in Japan [20, 23, 36–41]: Type I
with small and regular pit openings suggesting a normal
mucosa. Type II with large and regular stellar pit openings
suggesting a non-neoplastic, hyperplastic lesion. Types
IIIL, IIIS, IV, IV, Vi, VN with sinuous short, long, or
branched crests, suggesting neoplasia and progression from
a low- to a high-risk of malignancy. In adenomas, less than
Fig. 1 Superficial adenocarci-
noma of stomach at angulus,
staged T1,N0. At left, standard
vision: a flat area with a red-
dened appearance. At right,
indigocarmine chromoscopy: a
10 mm long depressed lesion,
reddened in depth with clear
borders; classified 0-IIc
Fig. 2 Advanced adenocarcino-
ma of stomach at angulus,Staged
T3,N1. At left, standard vision: a
flat reddened area surrounded by
a swollen margin. At right, indi-
gocarmine chromoscopy: a de-
pression surrounded by multiple
nodules, 15 mm in diameter. Not
classified as a superficial lesion
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10 mm in diameter a pit pattern in categories IIIL or IV
confirms a relatively low potential of evolution to adeno-
carcinoma. The degree of irregularity of the pit pattern Vi
predicts the depth of invasion in the submucosa below or
above the limit of 1,000 µm. The terminology de novo
cancer corresponds to small lesions with a flat or depressed
nonpolypoid morphology, and a pit pattern classified in
categories Vi to VN. Invasion in the sub-mucosa is
frequent, as is its progression to ulcerated advanced cancer.
In serrated adenomas, which frequently progress to serrated
carcinoma, the surface pit pattern varies from type II to type
IIIL in small lesions, to type IV in large serrated adenomas
and to type Vi or VN in serrated carcinomas.
The microvascular network
Subepithelial capillaries are explored in transparency (no
chromoscopy) during endoscopy, or with NBI where small
vessels are clearly contrasted in dark green. In the normal
mucosa the subepithelial capillaries reproduce the architec-
ture of the surface and vary with the site.
In the squamous epithelium of the esophagus intrapapillary
capillary loops (IPCL) show a hair-clip appearance. In
neoplastic lesions the vascular pattern varies from IPCL to a
punctuated pattern with tumoral neoangiogenesis and devel-
opment of vessels with an irregular and larger diameter,
predictive of depth of invasion [42].
In the columnar lined esophagus the microvascular
network at the surface of neoplastic areas has some relevance
to the depth of invasion. Slight vascular alterations suggest
low grade neoplasia and severe vascular alterations suggest
high grade non-invasive or invasive neoplasia [43].
In the stomach subepithelial capillaries form a honey-
comb network around the neck of gastric pits in the oxyntic
mucosa and present as coiled subepithelial capillaries in the
antral mucosa. The surface of intramucosal cancer shows
abnormal vessels with a mesh, coil or corkscrew pattern
according to the differentiation of the tumor [24, 44].
Fig. 3 Hyperplastic sessile
polyp in the colon. At left,
standard vision: a sessile lesion
with a small nodule at on ex-
tremity. At right, indigocarmine
chromoscopy: the lesion is
10 mm in length, with a pit
pattern type II with large open-
ings; classified 0-IIa + Is
Fig. 4 Laterally spreading
lesion (LST) in the colon with
high grade intraepithelial neo-
plasia. At left, standard vision: a
protruding nodule 6 mm in
diameter surrounded by a
slightly surelevated area with
uncertain limits. At right, indi-
gocarmine chromoscopy: the
lesion is over 25 mm in length.
Classified 0 IIa + Is and as a
nodular mixed type of granular
LST
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In the colon capillaries ensure a hexagonal network around
the pits. The successive categories of pit pattern—Faint—
Network—Dense—Irregular—Sparse—correspond to the
transition from non-neoplastic to malignant neoplasia [45].
Pragmatic classification and treatment decision
Application to columnar epithelium
The next step after endoscopic detection of a superficial lesion
developed in the columnar epithelium in the esophagus with
columnar metaplasia, in the stomach or the large bowel, is
treatment decision. The options are as follows:
1 - no treatment.
2 - endoscopic mucosal resection or EMR which is
limited by its inability to achieve en bloc resection
for lesions larger than 25 mm. This limit is overcome
in the new technique of endoscopic submucosal
dissection (ESD); however the procedure requires
more time and technical skill, and needs to be
standardized for application in the colon.
3 - surgery.
The legitimacy of treatment decision is confirmed by the
results of histopathology, using the Vienna classification of
neoplasia in the columnar epithelium into five categories of
which categories 1 and 2 apply to non-neoplastic lesions. A
strategy of endoscopic diagnosis with prediction of histology
based upon high resolution and magnification combined with
chromoscopy or NBI technique, is accessible to most
endoscopy units. The following scale of risk of lymph node
invasion and progression to advanced cancer can be proposed:
No risk of lymph node invasion This corresponds to
categories 1 and 2 in Vienna classification and applies to
normal epithelium, inflammation and small hyperplastic
polyps in the colon less than 10 mm in diameter, which are
considered as non-neoplastic lesions. Treatment decision is
based on size: small hyperplastic polyps are not treated,
polyps larger than 10 mm and sessile serrated lesions are
resected. Surveillance is optional in absence of treatment.
Low risk of lymph node invasion This corresponds to
categories 3 and 4-1 to 4-4 of the Vienna classification
and applies to low-grade intraepithelial neoplasia and non-
invasive high-grade intraepithelial neoplasia, In the stom-
ach and colon a well-differentiated intra-mucosal carcinoma
with low-grade cell atypia is also included in this category
because the risk of lymph node metastasis is considered to
be near to nil. Endoscopic resection of the lesion is
proposed. Follow-up is required, with surveillance intervals
adapted according to the histopathology.
Intermediate risk of lymph node invasion This corresponds
to category 4-4 in the Vienna classification and partly to
category 5. It involves three types of lesions: differentiated
intra-mucosal carcinoma with high-grade cellular atypia; -
poorly differentiated intra-mucosal carcinoma with signet
ring cells; - well differentiated sub-mucosal carcinoma with
depth of invasion in the submucosa less than 500 µm in
stomach and over 1,000 µm in colon and with low-grade
cell atypia. The risk of lymph node metastasis is estimated
from 1 to 4.8%. There is an option between endoscopic or
surgical resection. Surveillance at short intervals is required
after treatment. Surgery is recommended if the histopathol-
ogy reveals a high-risk lesion.
High risk of lymph node invasion This corresponds to
category 5 in the Vienna classification including two types
of lesions: - sub-mucosal poorly differentiated carcinoma; -
well-differentiated sub-mucosal carcinoma with high-grade
cell atypia or invasion deeper than 500 µm in stomach or
1,000 µm. Surgical treatment with/without neo-adjuvant
therapy is required as well as surveillance after treatment.
Fig. 5 Laterally spreading
lesion (LST) in the colon with
high grade intraepithelial neo-
plasia. At left, standard vision: a
sessile lesion 20 mm in diameter
with sharp limits and a central
depression. At right, indigocar-
mine chromoscopy and magni-
fication: epithelial crests show a
villous pattern. Classified as
0-IIa and as a nodular type of
granular LST
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Application to squamous epithelium in the esophagus
A specific classification taking in account the structure of
the squamous epithelium in the esophagus is justified: in
the mucosa the risk of lymph node invasion is not nil when
there is invasion of the lamina propria below the epithelial
layer. Intramucosal squamous cell cancer is classified with
respect to the depth of invasion as intraepithelial, micro-
invasive, or intramucosal: when there is deep invasion of
the submucosa, a superficial carcinoma is classified as
advanced cancer. Concerning lymph node metastases—the
risk is still extremely low (less than 2%) in superficial
cancer classified m1 or m2 which correspond to intra-
epithelial and to microinvasive cancer; endoscopic treat-
ment is recommended—the level of the risk is intermediate
and already sizable (just under 20%) in cancer classified m3
and the choice between endoscopic treatment or surgery
depends on the health status of the patient. When there is
sub-mucosal invasion, the risk is moderate is sm1 cancer
but extremely high (40%) is sm2 or sm3 cancer. Actually
endoscopic resection is still recommended if the invasion is
less than 200 µ; over this limit the indication is surgery. The
endoscopic treatment of a superficial neoplastic lesion in
the squamous stratified epithelium of the esophagus is
legitimate in approximately 20% of type 0-IIa lesions, 39%
of type 0-IIc lesions and 69% of type 0-IIb lesions.
Digestive endoscopy in screening
Endoscopic surveillance in the prevention of digestive
cancer
Surveillance, refers to endoscopy scheduled at regular
intervals from 2 to 5 years, independently of symptoms,
in those patients who do not have cancer, but who are at
increased risk. For the esophagus surveillance is justified in
persons having high consumption of alcohol and tobacco,
or antecedents of cancer in the upper aero-digestive tract, in
persons having columnar metaplasia in the esophagus in the
male sex with a prolonged symptomatic history of GERD,
continuous smoking, in presence of a peptic stricture or a
esophageal ulcer at endoscopy. For the stomach the most
frequent reason for surveillance is the presence of chronic
acquired atrophic gastritis in the postoperative stomach and
in pernicious anemia. For the colon this applies to persons
having a genetic predisposition to colorectal cancer in their
family without germline mutation type FAP or HNPCC.
Screening
Secondary prevention of digestive cancer aims to early
detection at a curable stage in asymptomatic persons. Early
detection of confirmed cancer reduces cancer mortality
without impact on incidence. Early detection and treatment
of precancerous lesions has in addition an impact on
incidence. Organized population based (mass screening)
and individual screening (opportunistic screening) are
complementary and variable situations occur in individual
detection. Population based screening associates a relatively
simple filter test, and a diagnostic test in persons with a
positive test. In the digestive tract upper GI endoscopy or
colonoscopy are the gold standard diagnostic tests. For
individual opportunistic screening, endoscopy is the prima-
ry procedure. Limiting factors in the benefit of early
detection, and treatment of neoplastic lesions include—the
degree of compliance to the detection procedure or to recall
for treatment in persons positive to the test—the over-
detection and over-treatment of lesions with a very low risk
of progression to malignancy, - the miss-rate for small, but
evolutive lesions, often responsible of interval cancers after
a negative exploration.
For esophageal squamous cell cancer, opportunistic
endoscopic screening may be proposed to persons having
high consumption of alcohol and tobacco, or antecedents of
cancer in the upper aero-digestive tract. In China, in areas
of high risk, population based screening campaigns based
on cytology smears and also on upper GI endoscopy have
been conducted.
For adenocarcinoma in the columnar lined esophagus,
the incidence is too low to justify mass screening protocols,
and there is only limited evidence on the benefit of
screening persons with unsedated transnasal endoscopy
and capsule endoscopy.
For adenocarcinoma in the stomach, gastroscopy in spite of
its efficacy, has a significant miss rate for early cancer
evaluated at 19% in a Japanese study. The consensus view is
that screening for gastric cancer does not deserve a public
Health Policy outside of Japan. In this country mass
screening, based on photofluorography, as a filter test
reaches a large proportion of the population and the
percentage of ever-screened subjects in Japan is estimated
around 60%. The serum pepsinogen test, has shown
efficacy as a filter test alternative to photofluorography in
screening protocols. However opportunistic screening
with upper GI endoscopy is still the major source of
detection for early gastric cancer.
Screening for colorectal cancer is now frequently
supported by the Health Policies of most developed
countries. It is based on a simple filter test, the fecal occult
blood test (guaiac or immunological) followed by colono-
scopy in persons positive to the test. Screening with
primary colonoscopy is also developing rapidly [46]; the
role of nonpolypoid lesions is now acknowledged in
Western countries [47]. In spite of its efficacy [48] the
technique of colonoscopy still deserves to be improved and
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the proximal colon (cecum and ascending colon) is the
preferential site of large but poorly visible neoplastic
lesions easily missed during a screening colonoscopy. A
population-based, case-control study conducted in Ontario,
Canada [49], confirmed that there was no protection
afforded by a previous colonoscopy for proximal cancer.
There was a sizable reduction in the risk of distal colorectal
cancer but no impact on death from right-sided CRC. This
result was confirmed by a further similar study conducted
in Germany. Interval cancers revealed a few years after a
negative colonoscopy often correspond to missed lesions
during the initial exploration.
(Illustrations with courtesy from Annick Chavaillon)
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